Metabolomics Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

The metabolomics market was valued at USD 2.81 Billion in 2025. It is poised to grow at a CAGR of 12.36% during the forecast period of 2026-2035, and reach USD 9.01 Billion by 2035. The market growth is driven by the rising adoption of precision medicine, increasing biomarker discovery research, and growing investments in omics technologies, enabling advanced disease profiling and personalized therapeutic development.

Q1 2026 Market Updates

Geopolitical Impact of Iran, US, and Israel War on the Metabolomics Market

United States: The Metabolomics Market, a key segment of the global economy, is experiencing a complex operating environment in Q1 2026 as a direct consequence of the US-Israel-Iran war. 31 force majeure declarations by polymer suppliers, polypropylene and polyethylene price spikes, and chemical manufacturer surcharges of up to 30% are flowing through supply chains. U.S. consumer inflation is projected at 4.2% for 2026, above pre-war forecasts, with fuel costs above USD 4 per gallon compressing household discretionary budgets. Retail supply chains are absorbing the combined impact of 30% higher freight costs, 15-20% packaging material inflation, and rising transport fuel costs, compressing retailer margins. Consumer spending caution is growing as gasoline prices above USD 4 per gallon and 4.2% projected inflation compress household discretionary budgets.

Iran: Iran's domestic Metabolomics sector has been effectively suspended by the conflict. US-Israeli strikes on industrial and civilian infrastructure across Tehran, Mashhad, Isfahan, and other major cities have disrupted all commercial activity. Power outages from attacks on electricity generation facilities have halted manufacturing operations, and the collapse of the commercial banking and logistics system has eliminated any residual trade flows. The broader humanitarian crisis, with over 1,900 casualties and 4,000+ civilian buildings damaged, has redirected the entire Iranian economy toward survival rather than production or consumption.

Israel: Israel's Metabolomics sector is experiencing near-term disruption from wartime conditions. Consumer spending on non-essential categories has declined as millions of Israelis regularly shelter from missile and drone alerts. Supply chain logistics are disrupted by regional airspace closures, elevated war-risk insurance premiums, and the suspension of major carrier services through the region. International business partnerships with Israeli companies have been temporarily suspended. Post-conflict reconstruction and recovery demand is expected to provide meaningful demand acceleration across affected market segments once operational conditions normalize.

Key Market Trends and Insights

• By product and services, metabolomics bioinformatics tools and services held approximately 50% share in the historical period.
• By indication, cancer dominated the market with over 44% share in the historical period.
• By region, North America contributed above 41% of the market share in the historical period.

Market Size and Forecast

• Market Size (2025): USD 2.81 Billion
• Projected Market Size (2035): USD 9.01 Billion
• CAGR (2026-2035): 12.36%

Metabolomics Market Overview

The market is experiencing steady growth, driven by expanding applications in precision medicine, biomarker discovery, and drug development. Advancements in analytical technologies such as mass spectrometry and chromatography are enhancing data accuracy and throughput. Increasing research funding and integration with genomics and proteomics are further supporting metabolite profiling adoption across pharmaceutical, clinical, and academic research settings globally. The market reached a value of approximately USD 2.81 Billion in 2025.

Metabolomics Market Growth Drivers

Expanding Clinical Translation and Multiomics Infrastructure to Drive the Market Adoption

The rising pharmaceutical R&D expenditure and the growing adoption of multiomics workflows are accelerating the market expansion. Increasing outsourcing to specialized analytical service providers is further strengthening clinical research efficiency and scalability. For instance, in September 2025, Biognosys announced to launch metabolomics and lipidomics services supporting targeted metabolomics approaches for drug discovery and clinical research, strengthening multi-omics capabilities and enhancing translational research pipelines globally, while untargeted metabolomics enables comprehensive detection of metabolic alterations in complex biological systems.

Metabolomics Market Trends

Key trends shaping the market include the growing integration of metabolomics in oncology research, increasing focus on immunotherapy safety profiling, and expanding applications in CAR-T therapy studies.

Growing Integration of Metabolomics in Oncology and Immunotherapy Safety Profiling to Enhance the Market Landscape

The rising integration of metabolomics in oncology research and increasing focus on immunotherapy safety profiling are shaping advanced clinical applications. Expanding CAR-T therapy studies are driving a deeper understanding of metabolic mechanisms linked to treatment response and toxicity. For instance, in February 2026, Metabolon applied its metabolomics platform in CAR-T cell therapy research, identifying metabolic signatures associated with neurotoxicity and improving therapeutic safety frameworks, where metabolic flux analysis is enabling deeper insights into cellular metabolic reprogramming.

Metabolomics Market Segmentation

Market Breakup by Product and Services

• Metabolomics Instruments
• Separation Tools
• Detection Tools
• Metabolomics Bioinformatics Tools and Services

Market Breakup by Application

• Biomarker Discovery
• Drug Discovery
• Toxicology Testing
• Nutrigenomics
• Functional Genomics
• Personalized Medicine
• Other Applications

Market Breakup by Indication

• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Inborn Errors of Metabolism
• Other Indications

Market Breakup by End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Others

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Metabolomics Market Share

Cancer Expected to Dominate the Market Segment by Indication

The market segmentation based on the indication include cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and other indications. Among these, cancer dominated the segment, accounting for over 44% of the market share in the historical period. The high share is attributed to increasing applications in early detection, treatment monitoring, and therapeutic research. The growing emphasis on biomarker discovery has significantly enhanced oncology research outcomes, supporting precision medicine approaches and driving sustained demand within the metabolomics market.

Metabolomics Market Analysis by Region

The regions included in the market are North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to lead the market, accounting for approximately 41% of the total market share in the historical period, supported by strong research infrastructure and significant funding. The region benefits from advanced analytical capabilities and early technology adoption. Increasing use of mass spectrometry across pharmaceutical and academic institutions is further strengthening market growth, enabling high-throughput analysis and improved metabolite identification accuracy.

Leading Players in the Metabolomics Market

The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Agilent Technologies, Inc.

Founded in 1999 and headquartered in Santa Clara, California, Agilent Technologies provides analytical instruments, software, and services supporting life sciences and diagnostics. Its portfolio includes chromatography and spectroscopy platforms widely used in metabolite profiling applications. The company continues to strengthen its position through advanced analytical solutions supporting precision medicine and biomarker research.

Thermo Fisher Scientific, Inc.

Established in 2006 and based in Waltham, Massachusetts, Thermo Fisher Scientific offers analytical instruments, reagents, and laboratory services. Its portfolio spans mass spectrometry and chromatography solutions, supporting mass spectrometry-driven metabolomics workflows. Its strong global presence and integrated solutions portfolio reinforce its leadership in metabolomics and broaden life sciences applications.

Bruker Corporation

Founded in 1960 and headquartered in Billerica, Massachusetts, Bruker Corporation specializes in high-performance scientific instruments, including NMR and mass spectrometry platforms. Its solutions are integral to NMR spectroscopy applications in metabolomics research. The company’s focus on high-precision technologies enhances its role in advanced metabolomics and structural biology research.

Shimadzu Corporation

Established in 1875 and headquartered in Kyoto, Japan, Shimadzu Corporation develops analytical and medical systems, including chromatography and mass spectrometry instruments. Its offerings support targeted metabolomics studies across clinical and research settings. Its continuous innovation in analytical instrumentation supports expanding applications in clinical diagnostics and life sciences.

Other key players in the market are Bio-Rad Laboratories, Inc., Metabolon, Inc., PerkinElmer Inc., Human Metabolome Technologies, Bioanalytical Systems, Inc., Danaher Corporation.

Key Questions Answered in the Metabolomics Market

• What was the metabolomics market value in 2025?
• What is the metabolomics market forecast outlook for 2026-2035?
• What major factors aid the demand for metabolomics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market’s major drivers, opportunities, and restraints?
• What are the major metabolomics market trends?
• Which products and services are expected to dominate the market segment?
• Which application is expected to dominate the market segment?
• Which indication is expected to dominate the market segment?
• Which end user is expected to dominate the market segment?
• Who are the key players in the metabolomics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?